CLINICAL TRIAL / NCT04613596

The Phase 2 portion of this study will evaluate the efficacy and safety of MRTX849 as monotherapy and in combination with pembrolizumab. There will be 3 cohorts of patients, all of whom have KRAS G12C mutation, have advanced or metastatic NSCLC, and are candidates for first-line treatment. 2 cohorts have PD-L1 TPS score <1% and are randomized to MRTX849 monotherapy or MRTX849 in combination with pembrolizumab. The 3rd cohort has PD-L1 TPS score of 1% or higher and is treated with MRTX849 and pembrolizumab

     The Phase 3 portion of the study will randomize patients with nonsquamous NSCLC with KRAS G12C mutation and TPS <50% in the first-line setting to adagrasib plus pembrolizumab or pembrolizumab plus chemotherapy. Primary efficacy endpoints are PFS and OS. Secondary and exploratory objectives include evaluation of secondary efficacy endpoints, safety and tolerability, adagrasib PK, PROs, and correlative genomic biomarkers for the combination regimen in the study population.

     MRTX849 is an orally available small molecule inhibitor of KRAS G12C, and Pembrolizumab (KEYTRUDA®) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Inclusion Criteria:

         - Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS

         - Phase 3: Histologically confirmed diagnosis of unresectable or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS <50%

         - Phase 3: Presence of evaluable or measurable disease per RECIST

         - Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:

             1. No evidence of brain metastases

             2. Untreated brain metastases not needing immediate local therapy

             3. Previously treated brain metastases not needing immediate local therapy

        Exclusion Criteria:

         - Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).

         - Phase 2: Active brain metastases

         - Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:

             1. Any untreated brain lesions > 1.0 cm in size

             2. Any brainstem lesions

             3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of > 10 mg of prednisone (or equivalent) prior to randomization.

             4. Have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy

         - Phase 3: Radiation to the lung > 30 Gy within 6 months prior to the first dose of study treatment